Abiraterone + ADT vs ADT only
Discontinued treatment due to adverse events measured at a median · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT probably leads to higher discontinued treatment due to adverse events measured at a median compared with ADT alone (moderate certainty).
1 finding from 1 review
- Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes onlyRR 1.5 [1.17, 1.92]1 study · 1199 participantsModerate